RGNX (regenxbio.com) Annual Net Income

Corporate emblem and logo of regenxbio.com (RGNX)

This price chart for REGENXBIO Inc. (RGNX) reflects profit dynamics currently priced in at -0.19. The business focuses on developing innovative treatments through gene modification. The company's success relies on the test results of therapies for the nervous system and vision, as well as external financing. A strong team of scientists, retained through a stock option system, ensures R&D stability.

Company Net Income: regenxbio.com (RGNX) for 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for REGENXBIO (RGNX)

- stock value and consensus price forecast:
Market Price REGENXBIO Corp|RGNX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization REGENXBIO Corp|RGNX - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share REGENXBIO|RGNX - Company Book Value|Capitalization to Book Value Ratio regenxbio.com|RGNX - Cumulative Company Assets
- debt burden and liquidity indicators:
Debt to Equity Ratio REGENXBIO Inc.|RGNX - Long-Term Debt to Capital|Short-Term Debt to Equity REGENXBIO Inc|RGNX - Company Aggregate Debts|Debts to Net Assets REGENXBIO Corp|RGNX - Company Long-Term Debt|Short-Term Debt REGENXBIO|Intermediate Coverage Ratio regenxbio.com
- company profitability and valuation multiples indicators:
RGNX - Net Profit
Fundamental valuation:RGNX - REGENXBIO Corp
Brand item of REGENXBIO Inc

The indicator is calculated as the difference between total revenues and all operating and non-operating expenses. This metric determines the actual efficiency of the business, making it possible to identify hidden financial drawdowns prior to the publication of financial statements. For REGENXBIO Inc. (RGNX), profit is generated through royalties from the use of patents for AAV9 vectors. The net income trend of the organization reflects the monetization of intellectual property. Analyzing the curve helps avoid purchasing the asset at its peak.

Main competitors

Company Net Income Tempus AI (TEM)|QGEN (Qiagen N.V.) - Net Profit|IONS - Annual Net Income|Net Profit RGEN|RNA - Company Net Income|Company Net Income CRISPR Therapeutics Corp CRSP|WGS: Company Profit|RARE: Net Income|BEAM (beamtx.com) - Company Profit|SRPT: Net Profit|TWST (Twist Bioscience Inc) - Company Net Income|TXG (10x Genomics Corp) - Net Profit|Intellia Corp (NTLA) - Net Financial Result|Company Net Income Stoke Therapeutics (STOK)|BLFS - Company Net Income|Wave Life Sciences Ltd. - Net Income|Final Profit MAZE|Sionna Pharma - Net Profit|Net Financial Result Prime Medicine Bio PRME|Taysha Gene Therapies (TSHA) - Company Net Income|Company Profit QURE|MGTX (MeiraGTx) - Net Profit|Net Income Solid Biosciences Inc (SLDB)|Net Income OCGN (Ocugen Corp)|Net Financial Result PacBio Corp|Company Net Income Benitec Biopharma Inc. BNTC|Final Profit DSGN|Rocket Pharmaceuticals, Inc. - Net Profit|Annual Net Income 4DMT (FDMT)|lexeotx.com (LXEO) - Company Net Income|Company Profit KRRO|Net Income EDIT|Company Profit SLN (silence-therapeutics.com)|Net Profit PRQR|codexis.com - Company Profit|Company Net Income Sangamo SGMO|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|DTIL - Net Profit|generationbio.com (GBIO) - Company Net Income|Boundless Bio Inc. - Final Profit|XCUR (Exicure Inc.) - Net Profit|Company Net Income Celsion Corporation IMNN|Net Profit PHIO|mustangbio.com (MBIO) - Annual Net Income|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Bionano Genomics Inc. (BNGO) - Company Net Income|APDN - Company Net Income|BLUE (bluebird bio, Inc) - Company Profit|IPA (immunoprecise.com) - Net Income|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Company Net Income RGLS|Net Profit SYRS|Net Financial Result Telesis Bio, Inc|Company Net Income TRACON Pharmaceuticals TCON|unitybiotechnology.com (UBX) - Company Net Income